Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma

NCT02574533 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT02574533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02574533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Lead sponsor
Gradalis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2015
Completion date
September 30, 2017
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, melanoma, melanoma recurrent